LEXARIA BIOSCIENCE CORP. Impairment of Intangible Assets, Finite-lived
LEXARIA BIOSCIENCE CORP. (LEXX) reported Impairment of Intangible Assets, Finite-lived of $0 for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. impairment of intangible assets, finite-lived for the quarter ending 2026-05-31 was $0.00.
- LEXARIA BIOSCIENCE CORP. impairment of intangible assets, finite-lived for the quarter ending 2025-08-31 was $213.82K.
- LEXARIA BIOSCIENCE CORP. impairment of intangible assets, finite-lived for the quarter ending 2025-05-31 was $0.00.
- LEXARIA BIOSCIENCE CORP. impairment of intangible assets, finite-lived for the quarter ending 2024-08-31 was $0.00.
- LEXARIA BIOSCIENCE CORP. impairment of intangible assets, finite-lived for fiscal 2025 was $247.36K, a 327.70% increase from fiscal 2024.
- LEXARIA BIOSCIENCE CORP. impairment of intangible assets, finite-lived for fiscal 2024 was $57.84K.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2026-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | $0.00 10-Q · filed 2026-07-13 | ||
| 2026-02-28 | $0.00 10-Q · filed 2026-04-13 | |||
| 2025-08-31 | $213.82K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $213.82K derived: sum of 2 quarters · filed 2026-07-13 | $247.36K 10-K · filed 2025-11-28 | |
| 2025-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | $33.54K 10-Q · filed 2026-07-13 | ||
| 2025-02-28 | $33.54K 10-Q · filed 2026-04-13 | |||
| 2024-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $57.84K 10-K · filed 2025-11-28 | ||
| 2024-05-31 | $57.84K 10-Q · filed 2025-07-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |